- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05534009
Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Background: Protection from SARS-CoV-2 infection is known to occur soon after vaccination or natural disease, fading over time. Although protection from serious illness does occur, protection from infection is insufficient and the impact of each variant and of each vaccine or vaccine schedule is a matter of continuous study. Recruiting participants from countries with different vaccines and vaccine schedules is of upmost importance to analyse these relationships and breakthrough infections. Study objectives: The EuCARE-HCW study contributes with data and samples from
HCW to EuCARE-IMMUNITY study that will analyse the NtAb and CMI to different SARS- CoV-2 variants following any combination of natural infection and vaccination. Specific
objectives include:
- to collect data and biological material from COVID-19 healthcare workers in 9 clinics from 8 countries and 3 continents.
- Enrolment of HCW with an immunogenic event, either vaccination or infection.
- Periodic collection of serum and whole blood every 4 months since enrolment and during 12-24 months (depending on how long immunity persists).
Sample preparation, storage and shipment to central EuCARE laboratories where WP2 study group will analyse natural and artificial immunity to SARS-CoV-2 variants (EuCARE-IMMUNITY), namely:
- Analyse the magnitude, breadth and duration of immunity following natural infection and/or vaccination.
- Define the cross-immunity among the different viral variants.
- Analyse the immune escape in a comprehensive set of combinations of vaccines and natural infection(s).
To accomplish the above objectives, WP2 will test:
- Neutralising antibodies
- Cellular immunity
- Viral sequences
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: FRANCESCA INCARDONA, DR
- Numéro de téléphone: +393356112830
- E-mail: francesca.incardona@euresist.org
Lieux d'étude
-
-
-
Düsseldorf, Allemagne
- Recrutement
- Heinrich Heine University
-
Contact:
- Bjoern Erik Jensen, DR
- E-mail: Bjoern-ErikOle.Jensen@med.uni-duesseldorf.de
-
-
-
-
-
Milan, Italie
- Recrutement
- Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo
-
Contact:
- ANTONELLA D'ARMINIO MONFORTE, PROF
- Numéro de téléphone: +390281843045-6
- E-mail: antonella.darminio@unimi.it
-
Milan, Italie
- Recrutement
- Ieo Istituto Europeo Di Oncologia
-
Contact:
- SARA GANDINI, DR
- E-mail: sara.gandini@ieo.it
-
-
-
-
-
Lisbon, Le Portugal
- Recrutement
- Centro Hospitalar de Lisboa Ocidental
-
Contact:
- CRISTINA TOSCANO, MD
- Numéro de téléphone: +351 210432541
- E-mail: ctoscano@chlo.min-saude.pt
-
-
-
-
-
Vilnius, Lituanie
- Recrutement
- Viesoji Istaiga Vilniaus Uiversiteto Ligoninė Santaros klinikos
-
Contact:
- DANIEL NAUMOVAS, DR
- E-mail: daniel.naumovas@santa.lt
-
-
-
-
-
Villahermosa, Mexique
- Recrutement
- Hospital Juan Ghaham Casasus
-
Contact:
- Gibran Rubio Quintanares, DR
- Numéro de téléphone: +49 6103 77 2125
- E-mail: Gibran.Rubio@pei.de
-
-
-
-
-
Hanoi, Viêt Nam
- Recrutement
- Bach Mai Hospital
-
Contact:
- CUONG DO DUY, MD
- E-mail: doduy.cuong@bachmai.edu.vn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
For each subject baseline will be the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline.
Health CareWorkers can be enrolled in the category of:
(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection. However, infections diagnosed during the first wave of the epidemic are suitable for the analysis of natural immunity to SARS-CoV-2 because vaccination was administered several months later.
La description
Inclusion Criteria:
The study subjects will be selected based on the following inclusion criteria:
- Adult (>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status.
- For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
- Having a signed informed consent when required by ethical approval
Exclusion Criteria: NONE
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Autre
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Heath care workers (HCW)
Adult (>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status.
For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
|
The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved. HCWs can be enrolled in the category of: (i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of HCW involved in the study
Délai: through study completion, an average of 3 years
|
To collect the higher possible number of data and biological materials from the HCWs of the participating Units
|
through study completion, an average of 3 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: CRISTINA TOSCANO, DR, Centro Hospitalar de Lisboa Ocidental (CHLO)
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- EuCARE-HCW
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- Protocole d'étude
- Plan d'analyse statistique (PAS)
- Formulaire de consentement éclairé (ICF)
- Rapport d'étude clinique (CSR)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur COVID-19 [feminine]
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkPas encore de recrutementSyndrome post-COVID-19 | Longue COVID | Longue Covid19 | État post-COVID-19 | Syndrome post-COVID | Condition post-COVID-19, non précisée | État post-COVIDPays-Bas
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlComplétéSéquelles post-aiguës de la COVID-19 | État post-COVID-19 | Long-COVID | Syndrome chronique du COVID-19Italie
-
Indonesia UniversityRecrutementSyndrome post-COVID-19 | Longue COVID | État post-COVID-19 | Syndrome post-COVID | Longue COVID-19Indonésie
-
Yang I. PachankisActif, ne recrute pasInfection respiratoire COVID-19 | Syndrome de stress COVID-19 | Effet indésirable du vaccin COVID-19 | Thromboembolie associée au COVID-19 | Syndrome de soins post-intensifs COVID-19 | AVC associé à la COVID-19Chine
-
Massachusetts General HospitalRecrutementSyndrome post-aigu COVID-19 | Longue COVID | Séquelles post-aiguës de la COVID-19 | Longue COVID-19États-Unis
-
Sheba Medical CenterInconnue
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecrutementPandémie de covid-19 | Vaccins contre le covid-19 | Maladie à virus COVID-19Indonésie
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecrutementCOVID-19 Pneumonie | Infection respiratoire COVID-19 | Pandémie de covid-19 | COVID-19 Syndrome de Détresse Respiratoire Aiguë | COVID-19-Pneumonie associée | Coagulopathie associée au COVID 19 | COVID-19 (maladie à coronavirus 2019) | Thromboembolie associée au COVID-19Grèce
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin No.2 Hospital et autres collaborateursRecrutementCOVID-19 [feminine] | Syndrome post-COVID-19 | COVID-19 post-aiguë | COVID-19 aiguëChine
-
Jonathann Kuo, MDActif, ne recrute pasInfection par le SRAS-CoV2 | Syndrome post-COVID-19 | Dysautonomie | Syndrome post-aigu COVID-19 | Longue COVID | Longue Covid19 | COVID-19 récurrent | COVID-19 post-aiguë | Infection COVID-19 post-aiguë | Séquelles post-aiguës de la COVID-19 | Dysautonomie comme trouble | Dysautonomie Syndrome d'hypotension... et d'autres conditionsÉtats-Unis